InnoCare Pharma Agrees With US FDA For Phase 3 Clinical Trail of Orelabrutinib for PPMS Patients; Shanghai Shares Up 4%
InnoCare Pharma Agrees With US FDA For Phase 3 Clinical Trail of Orelabrutinib for PPMS Patients; Shanghai Shares Up 4%
诺诚健华药业与美国FDA就Orelabrutinib用于PPMS患者的3期临床试验达成一致；上海股票上涨4%
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册